Neumora Therapeutics, Inc. (NMRA): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Neumora Therapeutics (NMRA) focuses on developing drugs for schizophrenia, depression, and dementia, where success depends on clinical trial outcomes. This chart illustrates that the asset's market valuation in terms of EV/EBITDA is 0.00, while the business relies on a stable US legal framework and the humanitarian status of the industry. However, global conflicts and sanctions could hinder the certification of new drugs due to logistics disruptions.
Metric breakdowns and analytics for Neumora Therapeutics Inc (NMRA)
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Neumora Therapeutics|NMRA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Neumora Therapeutics Inc|NMRA - Aggregate Debt Obligations|Debt to Book Value Neumora Corp|NMRA - Amount of Long-Term Liabilities|Company Short-Term Debts Neumora Therapeutics|Quick Ratio neumoratx.com
- business earnings and investment ratios data:
NMRA - Company Net Income|Expected Profit Neumora Therapeutics|NMRA - Company Value to Net Income|Forward P/E Multiple neumoratx.com|NMRA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neumora Therapeutics|NMRA - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Neumora Therapeutics|NMRA - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months neumoratx.com|NMRA - Earnings growth in current year|Expected earnings per share growth for next year Neumora Therapeutics
- revenue and sales details:
Summary company analysis:Neumora Therapeutics Inc (NMRA)
EV/EBITDA measures the value of a business, including net debt, relative to operating profit, determining the payback period of assets. By analyzing the EV/EBITDA trajectory of a company, an investor can identify capital overvaluation or an entry point when the multiple declines. This metric discounts future cash flows while accounting for debt load and tax obligations. For Neumora Therapeutics (NMRA), this is critical, as capitalization depends on future government procurement of drugs for treating psychiatric disorders.
Competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|SCLX (Scilex Holding Company) - Enterprise Value to EBITDA Ratio|TVGN (Tevogen Bio Holdings) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACOG (Alpha Cognition Corp) - EV/EBITDA Multiple|Cognition Therapeutics, Inc. - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IKT|SAVA (Cassava) - Business Value to Operating Income Before Depreciation|Assertio Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation COYA|VistaGen Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics OVID|ABOS: EV/EBITDA Multiple|CervoMed Corporation (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|JUNS (Jupiter Neurosciences) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp RLMD|EV/EBITDA Multiple Annovis Bio Corporation ANVS|gracetx.com - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics, Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings) - EV/EBITDA Multiple|MetaVia Inc (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|Total Company Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization passagebio.com PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Athira - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|ALZN (Alzamend Neuro, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)
